Payment overview · 2025
General Payments
$529.65
36 reported records · 10 companies
Healthcare provider profile · identity verified
Vijay N Kumar, M.D.,
Allopathic & Osteopathic Physicians|Family Medicine · NORTON, VA · NPI 1477747145
Verified facts
What the public records show
CMS Open Payments records show Vijay N Kumar, M.D., received $529.65 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 37.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Rexulti, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Symbicort by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $196.16 | 37.0% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $82.92 | 15.7% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.10 | 11.2% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $48.80 | 9.2% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.47 | 8.2% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $33.00 | 6.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.75 | 3.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.75 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.37 | 2.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.33 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $529.65 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $196.16 | 17 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $82.92 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $59.10 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $48.80 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $43.47 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $33.00 | 2 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 213 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
104 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
213 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 920 | 163 |
| Furosemide | Furosemide | 643 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 586 | 145 |
| Potassium Chloride | Potassium Chloride | 554 | 112 |
| Omeprazole | Omeprazole | 539 | 134 |
| Gabapentin | Gabapentin | 536 | 79 |
| Lisinopril | Lisinopril | 528 | 128 |
| Eliquis | Apixaban | 495 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 465 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 436 | 110 |
| Trazodone Hcl | Trazodone Hcl | 413 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 391 | 68 |
| Metformin Hcl | Metformin Hcl | 342 | 89 |
| Metoprolol Tartrate | Metoprolol Tartrate | 333 | 74 |
| Losartan Potassium | Losartan Potassium | 316 | 78 |
| Quetiapine Fumarate | Quetiapine Fumarate | 297 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 295 | 82 |
| Sertraline Hcl | Sertraline Hcl | 293 | 57 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 291 | 57 |
| Mirtazapine | Mirtazapine | 289 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 280 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 280 | 66 |
| Meloxicam | Meloxicam | 269 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 256 | 66 |
| Jardiance | Empagliflozin | 239 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 237 | 51 |
| Donepezil Hcl | Donepezil Hcl | 236 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 234 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 231 | 51 |
| Famotidine | Famotidine | 222 | 51 |
| Ropinirole Hcl | Ropinirole Hcl | 219 | 48 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 217 | 30 |
| Farxiga | Dapagliflozin Propanediol | 213 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 202 | 51 |
| Montelukast Sodium | Montelukast Sodium | 194 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 191 | 62 |
| Carvedilol | Carvedilol | 189 | 44 |
| Lorazepam | Lorazepam | 188 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 42 |
| Memantine Hcl | Memantine Hcl | 170 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 168 | 32 |
| Buspirone Hcl | Buspirone Hcl | 168 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 165 | 20 |
| Simvastatin | Simvastatin | 161 | 36 |
| Ibuprofen | Ibuprofen | 157 | 38 |
| Cephalexin | Cephalexin | 154 | 78 |
| Alprazolam | Alprazolam | 152 | 16 |
| Levetiracetam | Levetiracetam | 149 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 148 | 103 |
| Topiramate | Topiramate | 136 | 29 |
| Celecoxib | Celecoxib | 134 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 133 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 132 | 25 |
| Tramadol Hcl | Tramadol Hcl | 132 | 27 |
| Mounjaro | Tirzepatide | 130 | 21 |
| Allopurinol | Allopurinol | 129 | 32 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 128 | 27 |
| Ezetimibe | Ezetimibe | 125 | 24 |
| Atenolol | Atenolol | 123 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 123 | 22 |
| Azithromycin | Azithromycin | 120 | 76 |
| Divalproex Sodium | Divalproex Sodium | 118 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 116 | 29 |
| Trulicity | Dulaglutide | 113 | 16 |
| Fluconazole | Fluconazole | 105 | 58 |
| Januvia | Sitagliptin Phosphate | 104 | 19 |
| Linzess | Linaclotide | 104 | 24 |
| Ozempic | Semaglutide | 103 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 103 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 101 | 21 |
| Meclizine Hcl | Meclizine Hcl | 97 | 32 |
| Pregabalin | Pregabalin | 96 | 12 |
| Promethazine Hcl | Promethazine Hcl | 96 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 94 | 11 |
| Spironolactone | Spironolactone | 94 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 16 |
| Ondansetron Odt | Ondansetron | 91 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 11 |
| Bupropion Xl | Bupropion Hcl | 87 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 87 | 57 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 87 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 24 |
| Sucralfate | Sucralfate | 86 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 85 | 46 |
| Testosterone Cypionate | Testosterone Cypionate | 85 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | 11 |
| Torsemide | Torsemide | 84 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 26 |
| Levofloxacin | Levofloxacin | 79 | 53 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 17 |
| Alendronate Sodium | Alendronate Sodium | 77 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 32 |
| Methylprednisolone | Methylprednisolone | 72 | 52 |
| Cefdinir | Cefdinir | 70 | 51 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | 19 |
| Baclofen | Baclofen | 69 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 67 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 35 |
| Nystatin | Nystatin | 64 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 14 |
| Synthroid | Levothyroxine Sodium | 61 | suppressed |
| Diazepam | Diazepam | 58 | suppressed |
| Entresto | Sacubitril/Valsartan | 58 | suppressed |
| Finasteride | Finasteride | 58 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | suppressed |
| Bumetanide | Bumetanide | 57 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 56 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 55 | 19 |
| Prednisone | Prednisone | 55 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 54 | suppressed |
| Glimepiride | Glimepiride | 54 | 17 |
| Xarelto | Rivaroxaban | 54 | 11 |
| Clonazepam | Clonazepam | 52 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 52 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 51 | 15 |
| Nitroglycerin | Nitroglycerin | 50 | 24 |
| Prazosin Hcl | Prazosin Hcl | 50 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 37 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 48 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 48 | suppressed |
| Olanzapine | Olanzapine | 46 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 46 | suppressed |
| Valsartan | Valsartan | 46 | 12 |
| Ceftriaxone | Ceftriaxone Sodium | 45 | 24 |
| Lidocaine | Lidocaine | 45 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 45 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Methimazole | Methimazole | 43 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 42 | 11 |
| Lamotrigine | Lamotrigine | 42 | suppressed |
| Mupirocin | Mupirocin | 42 | 32 |
| Amoxicillin | Amoxicillin | 41 | 23 |
| Risperidone | Risperidone | 41 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 41 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 40 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 40 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 40 | suppressed |
| Cilostazol | Cilostazol | 39 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Lansoprazole | Lansoprazole | 38 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 37 | suppressed |
| Ranolazine Er | Ranolazine | 37 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 36 | 27 |
| Dapagliflozin | Dapagliflozin Propanediol | 36 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 35 | 15 |
| Naltrexone Hcl | Naltrexone Hcl | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 13 |
| Phenobarbital | Phenobarbital | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 31 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 31 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | 11 |
| Estradiol | Estradiol | 29 | suppressed |
| Insulin Lispro | Insulin Lispro | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Glipizide | Glipizide | 28 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 22 |
| Ketoconazole | Ketoconazole | 27 | 11 |
| Morphine Sulfate | Morphine Sulfate | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Fentanyl | Fentanyl | 26 | suppressed |
| Fycompa | Perampanel | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | 12 |
| Humalog Kwikpen U-200 | Insulin Lispro | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 21 | 21 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | 12 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Levemir | Insulin Detemir | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 17 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Entacapone | Entacapone | 16 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 13 |
| Naproxen | Naproxen | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Lorazepam Intensol | Lorazepam | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | 11 |
| Lidocaine Hcl | Lidocaine Hcl | 14 | 13 |
| Novolin R Flexpen | Insulin Regular, Human | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 13 | suppressed |
| Easy Comfort Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Safetyglide Insulin Syringe | Syringe,needle,insuln,sf,0.3ml | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Ultiguard Safepack-Pen Needle | Pen Needle, Diabetic,disp Unit | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $529.65 · 36 records | ABBVIE INC. | AUSTEDO XR, Auvelity, CAPLYTA, Cologuard Collection Kit, FARXIGA, NUZYRA, REXULTI, TRINTELLIX, VRAYLAR, XHANCE, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error